Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2000

01-08-2000 | Review

Fibroblast biology Synovial fibroblasts in rheumatoid arthritis: leading role or chorus line?

Authors: Dimitris Kontoyiannis, George Kollias

Published in: Arthritis Research & Therapy | Issue 5/2000

Login to get access

Excerpt

The continuing saga of the aetiology and pathogenesis of joint destruction in rheumatoid arthritis (RA) has often led to reassessment of the working hypotheses created to explain the phenomenon. Initial and current models set a protagonistic role for inflammatory and autoimmune cellular mediators in RA, and this notion has been well supported by a plethora of experimental data. However, it may have been biased by the relatively more easy access to experimental and clinical data regarding immune cell function and also, perhaps, by the overenthusiasm with which it was felt cellular immunology could explain chronic immunopathologies. Even from early investigations, however, it has been clear that for arthritis development, inflammatory and autoimmune processes actively interacted with a network of non-immune cell types, and that it was the effector activities of these cell types that resulted in cartilage and bone attack. Although, until recently, the non-immune constituents of the synovial lining were regarded as mere targets of the inflammatory milieu and as secondary players in the development of disease, more recent data provide serious grounds for considering these cells as dominant players in the aetiopathogenesis of RA. The series of reviews on synovial fibroblasts (SFs) presented in this issue of Arthritis Research aims to refocus attention on our current knowledge of the biology of SFs and their possible involvement in the development of RA. …
Literature
1.
go back to reference Edwards JCW: Fibroblast biology: development and differentiation of synovial fibroblasts in arthritis. Arthritis Res. 2000, Edwards JCW: Fibroblast biology: development and differentiation of synovial fibroblasts in arthritis. Arthritis Res. 2000,
2.
go back to reference Konttinen YT, Li T-F, Hukkanen M, Ma J, Xu J-W, Virtanen I: Fibroblast biology: signals targeting the synovial fibroblast in arthritis. Arthritis Res. 2000, Konttinen YT, Li T-F, Hukkanen M, Ma J, Xu J-W, Virtanen I: Fibroblast biology: signals targeting the synovial fibroblast in arthritis. Arthritis Res. 2000,
3.
go back to reference Ritchlin C: Fibroblast biology: effector signals released by the synovial fibroblast in arthritis. Arthritis Res. 2000, Ritchlin C: Fibroblast biology: effector signals released by the synovial fibroblast in arthritis. Arthritis Res. 2000,
4.
go back to reference Pap T, Müller-Ladner U, Gay RE, Gay S: Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000, Pap T, Müller-Ladner U, Gay RE, Gay S: Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000,
Metadata
Title
Fibroblast biology Synovial fibroblasts in rheumatoid arthritis: leading role or chorus line?
Authors
Dimitris Kontoyiannis
George Kollias
Publication date
01-08-2000
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar109

Other articles of this Issue 5/2000

Arthritis Research & Therapy 5/2000 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.